Hepion Pharmaceuticals Inc

NASDAQ:HEPA

0.78

+0.04 (+4.73%)

7:50:04 PM EDT: $0.78 0.00 (0.45%)

Products, Regulatory

Hepion Pharma Announces Positive Top Line Data For Low Dose Crv431 In Phase 2A 'Ambition' Clinical Trial For Treatment Of Advanced Nash

Published: 12/29/2020 21:32 GMT

Hepion Pharmaceuticals Inc (HEPA) - Hepion Pharmaceuticals Inc. - Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose Crv431 in Phase 2a 'ambition' Clinical Trial for Treatment of Advanced Nash.
Hepion Pharmaceuticals Inc - Crv431 Demonstrated to Be Generally Safe and Well Tolerated.
Hepion Pharmaceuticals - Phase 2a Study is Continuing With Higher Dose of 225 Mg Crv431, With Nash Patient Dosing Expected to Be Completed in Q1-2021.